<?xml version='1.0' encoding='utf-8'?>
<document id="24259648"><sentence text="Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination."><entity charOffset="30-42" id="DDI-PubMed.24259648.s1.e0" text="methotrexate" /><entity charOffset="47-60" id="DDI-PubMed.24259648.s1.e1" text="levetiracetam" /><entity charOffset="82-94" id="DDI-PubMed.24259648.s1.e2" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.24259648.s1.e0" e2="DDI-PubMed.24259648.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24259648.s1.e0" e2="DDI-PubMed.24259648.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s1.e0" e2="DDI-PubMed.24259648.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24259648.s1.e1" e2="DDI-PubMed.24259648.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s1.e1" e2="DDI-PubMed.24259648.s1.e2" /></sentence><sentence text="To report a case of delayed methotrexate (MTX) elimination while receiving concomitant levetiracetam"><entity charOffset="28-40" id="DDI-PubMed.24259648.s2.e0" text="methotrexate" /><entity charOffset="42-45" id="DDI-PubMed.24259648.s2.e1" text="MTX" /><entity charOffset="87-100" id="DDI-PubMed.24259648.s2.e2" text="levetiracetam" /><pair ddi="false" e1="DDI-PubMed.24259648.s2.e0" e2="DDI-PubMed.24259648.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24259648.s2.e0" e2="DDI-PubMed.24259648.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s2.e0" e2="DDI-PubMed.24259648.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24259648.s2.e1" e2="DDI-PubMed.24259648.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s2.e1" e2="DDI-PubMed.24259648.s2.e2" /></sentence><sentence text="" /><sentence text="A 46-year-old man with relapsed osteosarcoma of the base of the skull receiving high-dose MTX tolerated his first cycle of MTX with elimination to nontoxic MTX levels (≤0"><entity charOffset="90-93" id="DDI-PubMed.24259648.s4.e0" text="MTX" /><entity charOffset="123-126" id="DDI-PubMed.24259648.s4.e1" text="MTX" /><entity charOffset="156-158" id="DDI-PubMed.24259648.s4.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.24259648.s4.e0" e2="DDI-PubMed.24259648.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24259648.s4.e0" e2="DDI-PubMed.24259648.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s4.e0" e2="DDI-PubMed.24259648.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24259648.s4.e1" e2="DDI-PubMed.24259648.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s4.e1" e2="DDI-PubMed.24259648.s4.e2" /></sentence><sentence text="1 µmol/L) within 90 hours" /><sentence text=" After hospital discharge, the patient experienced seizures secondary to brain metastasis and started on levetiracetam, which was continued as maintenance therapy"><entity charOffset="105-118" id="DDI-PubMed.24259648.s6.e0" text="levetiracetam" /></sentence><sentence text=" The patient experienced delayed MTX elimination during cycles 2, 3, and 4 while receiving levetiracetam"><entity charOffset="33-36" id="DDI-PubMed.24259648.s7.e0" text="MTX" /><entity charOffset="91-104" id="DDI-PubMed.24259648.s7.e1" text="levetiracetam" /><pair ddi="false" e1="DDI-PubMed.24259648.s7.e0" e2="DDI-PubMed.24259648.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24259648.s7.e0" e2="DDI-PubMed.24259648.s7.e1" /></sentence><sentence text=" On average, elimination to nontoxic MTX levels took 130 hours (106-144 hours)"><entity charOffset="37-49" id="DDI-PubMed.24259648.s8.e0" text="MTX" /></sentence><sentence text=" Before the fifth cycle of MTX, lorazepam was substituted for the levetiracetam"><entity charOffset="27-30" id="DDI-PubMed.24259648.s9.e0" text="MTX" /><entity charOffset="32-41" id="DDI-PubMed.24259648.s9.e1" text="lorazepam" /><entity charOffset="66-79" id="DDI-PubMed.24259648.s9.e2" text="levetiracetam" /><pair ddi="false" e1="DDI-PubMed.24259648.s9.e0" e2="DDI-PubMed.24259648.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24259648.s9.e0" e2="DDI-PubMed.24259648.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s9.e0" e2="DDI-PubMed.24259648.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24259648.s9.e1" e2="DDI-PubMed.24259648.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s9.e1" e2="DDI-PubMed.24259648.s9.e2" /></sentence><sentence text=" MTX was eliminated to nontoxic levels within 95 hours"><entity charOffset="1-4" id="DDI-PubMed.24259648.s10.e0" text="MTX" /></sentence><sentence text=" During all cycles, the patient received standard supportive care and serum creatinine remained stable"><entity charOffset="76-86" id="DDI-PubMed.24259648.s11.e0" text="creatinine" /></sentence><sentence text=" No other drugs known to interact with MTX were administered"><entity charOffset="39-48" id="DDI-PubMed.24259648.s12.e0" text="MTX" /></sentence><sentence text="" /><sentence text="This possible drug interaction has only been reported once in the pediatric population" /><sentence text=" With a score of 6 on the Drug Interaction Probability Scale for evaluating causation of drug interactions, it is probable that the delayed MTX elimination was caused by an interaction with levetiracetam"><entity charOffset="190-203" id="DDI-PubMed.24259648.s15.e0" text="levetiracetam" /><entity charOffset="140-152" id="DDI-PubMed.24259648.s15.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.24259648.s15.e1" e2="DDI-PubMed.24259648.s15.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s15.e1" e2="DDI-PubMed.24259648.s15.e0" /></sentence><sentence text="" /><sentence text="Coadministration of levetiracetam and MTX may result in delayed elimination of MTX, increasing the likelihood of toxicity"><entity charOffset="20-33" id="DDI-PubMed.24259648.s17.e0" text="levetiracetam" /><entity charOffset="38-41" id="DDI-PubMed.24259648.s17.e1" text="MTX" /><entity charOffset="79-82" id="DDI-PubMed.24259648.s17.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.24259648.s17.e0" e2="DDI-PubMed.24259648.s17.e0" /><pair ddi="false" e1="DDI-PubMed.24259648.s17.e0" e2="DDI-PubMed.24259648.s17.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s17.e0" e2="DDI-PubMed.24259648.s17.e2" /><pair ddi="false" e1="DDI-PubMed.24259648.s17.e1" e2="DDI-PubMed.24259648.s17.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s17.e1" e2="DDI-PubMed.24259648.s17.e2" /></sentence><sentence text=" Consideration should be given to temporarily switching from levetiracetam to another antiepileptic (ie, lorazepam) to prevent this interaction"><entity charOffset="61-74" id="DDI-PubMed.24259648.s18.e0" text="levetiracetam" /><entity charOffset="105-114" id="DDI-PubMed.24259648.s18.e1" text="lorazepam" /><pair ddi="false" e1="DDI-PubMed.24259648.s18.e0" e2="DDI-PubMed.24259648.s18.e0" /><pair ddi="false" e1="DDI-PubMed.24259648.s18.e0" e2="DDI-PubMed.24259648.s18.e1" /></sentence><sentence text=" This is particularly important in those experiencing delayed elimination with prior cycles of concomitant MTX and levetiracetam or those at greater risk for MTX toxicity"><entity charOffset="107-110" id="DDI-PubMed.24259648.s19.e0" text="MTX" /><entity charOffset="115-128" id="DDI-PubMed.24259648.s19.e1" text="levetiracetam" /><entity charOffset="158-170" id="DDI-PubMed.24259648.s19.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.24259648.s19.e0" e2="DDI-PubMed.24259648.s19.e0" /><pair ddi="false" e1="DDI-PubMed.24259648.s19.e0" e2="DDI-PubMed.24259648.s19.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s19.e0" e2="DDI-PubMed.24259648.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24259648.s19.e1" e2="DDI-PubMed.24259648.s19.e1" /><pair ddi="false" e1="DDI-PubMed.24259648.s19.e1" e2="DDI-PubMed.24259648.s19.e2" /></sentence><sentence text="" /></document>